Human Lymphotoxin alpha1/beta2組換え体(リコンビナント)タンパク質 | Recombinant Human Lymphotoxin alpha1/beta2

R&D Systems社製の高品質なHuman Lymphotoxin alpha1/beta2の組換え体タンパク質(Recombinant Human Lymphotoxin alpha1/beta2)です。

※本製品は研究用です。研究用以外には使用できません。

※バルク包装品も承ります。お気軽にお問合せ下さい。

R&D Systems社組換え体タンパク質製品では通常ウシ血清アルブミン(BSA)をキャリアタンパク質として加えています。キャリアタンパク質を加えることで組換え体タンパク質の安定性が高まり、使用期限が長くなります。また、より濃度の低い溶液での保管も可能となります。CF製品はBSAが含まれない製品となります。一般的に細胞培養や、ELISAのスタンダードにはBSA含有製品を推奨しています。CF製品はBSAが影響してしまうアプリケーションに推奨されます。

Lymphotoxin alpha (LT-alpha ), and Lymphotoxin beta (LT-beta ) are pro-inflammatory TNF superfamily ligands that play important roles in immune system development (1, 2). The 25 kDa mature human LT-alpha is a secreted protein that shares 75% amino acid (aa) sequence identity with mouse and rat LT-alpha (3, 4). The 33 kDa mature human LT-beta is a type II transmembrane protein that shares 73% aa sequence identity with mouse and rat LT-beta within common regions of their extracellular domains (5). Relative to the human protein, mouse and rat LT-beta have a 66 aa or 65 aa insertion within the ECD, respectively. LT-alpha can be secreted as a homotrimer that binds and activates TNF RI/TNFRSF1A, TNF RII/TNFRSF1B, HVEM/TNFRSF14, and Troy/TNFRSF19 (6-8). LT-alpha is required for development of the spleen, lymph nodes, and Peyer’s patches (9). It also regulates T cell homing to the gut and IgA induction (10). In addition, LT-alpha can form membrane-associated heterotrimers with two copies of LT-beta on the surface of B, T, LTi, and ILC3 cells (2, 5, 11). The Lymphotoxin alpha 1/ beta 2 heterotrimer binds and activates the Lymphotoxin beta R/TNFRSF3 (LT beta R) which is expressed on macrophages, dendritic cells, hepatocytes, intestinal epithelial cells (IEC), follicular dendritic cells (FDC), and high endothelial venules (HEV) (2, 12, 13). LT beta R also serves as a receptor for LIGHT/TNFSF14 (14). LT-alpha 1/ beta 2 promotes the development of FDC networks and HEV in lymphoid tissue, the class switching of immature B cells for IgA production, and the production of homeostatic IL-22 by ILCs (10, 15-17). It can be shed by ADAM17 or MMP-8 mediated cleavage, and the released heterotrimer circulates in the serum and is elevated in synovial fluid of rheumatoid arthritis patients (18).